> 首页 > 产品 > 一抗 > 其他 > Anti-EGFR & Fc-gamma-RIIIA Reference Antibody (AFM24)

Anti-EGFR & Fc-gamma-RIIIA Reference Antibody (AFM24)

Anti-EGFR & Fc-gamma-RIIIA Reference Antibody (AFM24) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 99.5%.
The purity of Anti-EGFR & Fc-gamma-RIIIA Reference Antibody (AFM24) is 97.37%, determined by SEC-HPLC.
Afm24 bound to EGFR protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Afm24 bound hu-EGFR-His, and the EC50 was 0.044 nM.
Afm24 bound to CD16a protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Afm24 bound hu-CD16a-His, and the EC50 was 0.489 nM.
Afm24 bound to EGFR-CHO-K cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Afm24 bound to EGFR-CHO-K cells, and the EC50 was 4.075 nM.
The detected molecular weight of Anti-EGFR & CD16a/Fc-gamma-RIIIA Reference Antibody (Afm24) is 196.31 kDa.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P00533 & P08637
Reactivity	Human
Clonality	Bispecific
Isotype	IgG-scFv

Additional Information
Target/Specificity	ERBB1 / EGFR / HER1,FcgR3a / CD16a
Expression system	CHO

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.